

Stefania Paolini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5098135/publications.pdf>

Version: 2024-02-01

142
papers

7,207
citations

100601

38
h-index

68831

81
g-index

143
all docs

143
docs citations

143
times ranked

7528
citing authors

#	ARTICLE	IF	CITATIONS
1	Seeking and avoiding contact with Muslims at a Hijab Stall: Evidence for multilayer, multi-determined solidarity, courage, apathy, and moral outrage. <i>British Journal of Social Psychology</i> , 2022, 61, 214-252.	1.8	3
2	INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 1742-1753.	2.5	33
3	How do we get people into contact? Predictors of intergroup contact and drivers of contact seeking. <i>Journal of Social Issues</i> , 2021, 77, 38-63.	1.9	41
4	Bilinguals'™ and monolinguals'™ performance on a non-verbal cognitive control task: How bilingual language experience contributes to cognitive performance by reducing mixing and switching costs. <i>International Journal of Bilingualism</i> , 2021, 25, 189-204.	0.6	8
5	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. <i>Blood</i> , 2021, 137, 751-762.	0.6	183
6	Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients. <i>Leukemia Research</i> , 2021, 101, 106497.	0.4	3
7	Intergroup contact research in the 21st century: Lessons learned and forward progress if we remain open. <i>Journal of Social Issues</i> , 2021, 77, 11-37.	1.9	38
8	Emotions in Intergroup Contact: Incidental and Integral Emotions' Effects on Interethnic Bias Are Moderated by Emotion Applicability and Subjective Agency. <i>Frontiers in Psychology</i> , 2021, 12, 588944.	1.1	3
9	An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia. <i>Blood Advances</i> , 2021, , .	2.5	12
10	Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters. <i>Frontiers in Immunology</i> , 2021, 12, 804988.	2.2	5
11	Does intimacy counteract or amplify the detrimental effects of negative intergroup contact on attitudes?. <i>Group Processes and Intergroup Relations</i> , 2020, 23, 214-225.	2.4	10
12	MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2020, 105, 47-55.	1.1	4
13	Balance seeking opinion dynamics model based on social judgment theory. <i>Physica D: Nonlinear Phenomena</i> , 2020, 403, 132336.	1.3	8
14	Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant <i>Pseudomonas aeruginosa</i> Infections in Neutropenic Patients. <i>Microorganisms</i> , 2020, 8, 2055.	1.6	5
15	A Three-Gene Immune Signature Including <i>IDO1</i> , <i>BIN1</i> and <i>PLXNC1</i> Predicts Survival in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 35-36.	0.6	1
16	<i>Saprochaete clavata</i> infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature. <i>Mycoses</i> , 2019, 62, 1100-1107.	1.8	19
17	Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol. <i>Leukemia and Lymphoma</i> , 2019, 60, 3482-3492.	0.6	3
18	Mediating Effects of the eCoFit™ Physical Activity Intervention for Adults at Risk of, or Diagnosed with, Type 2 Diabetes. <i>International Journal of Behavioral Medicine</i> , 2019, 26, 512-521.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML. <i>New England Journal of Medicine</i> , 2019, 381, 1728-1740.	13.9	796
20	Acute Myeloid Leukemia Mutations: Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2721.	1.8	17
21	A confirmatory study of the relations between workplace sexism, sense of belonging, mental health, and job satisfaction among women in male-dominated industries. <i>Journal of Applied Social Psychology</i> , 2019, 49, 267-282.	1.3	37
22	Learning to fear outgroups: An associative learning explanation for the development and reduction of intergroup anxiety. <i>Social and Personality Psychology Compass</i> , 2019, 13, e12442.	2.0	8
23	Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia. <i>Cancers</i> , 2019, 11, 1654.	1.7	18
24	Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 312-318.	1.7	54
25	Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. <i>Cancer</i> , 2019, 125, 712-725.	2.0	49
26	Positive imagined contact is actively chosen: Exploring determinants and consequences of volitional intergroup imagery in a conflict-ridden setting. <i>Group Processes and Intergroup Relations</i> , 2019, 22, 511-529.	2.4	12
27	Bad Is Stronger Than Good for Stigmatized, but Not Admired Outgroups: Meta-Analytical Tests of Intergroup Valence Asymmetry in Individual-to-Group Generalization Experiments. <i>Personality and Social Psychology Review</i> , 2019, 23, 3-47.	3.4	54
28	Blinatumomab is safe and effective in relapsed and MRD-positive B-ALL CD19+ patients: The Bologna Compassionate Program Experience. <i>Journal of Clinical Oncology</i> , 2019, 37, e18522-e18522.	0.8	0
29	Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 1343-1343.	0.6	1
30	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. <i>Leukemia</i> , 2018, 32, 1609-1620.	3.3	80
31	Increased angiogenesis seems to correlate with inferior overall survival in myeloid sarcoma patients. <i>Polish Journal of Pathology</i> , 2018, 69, 254-265.	0.1	4
32	Seeking and avoiding intergroup contact: Future frontiers of research on building social integration. <i>Social and Personality Psychology Compass</i> , 2018, 12, e12422.	2.0	64
33	Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia. <i>BMC Cancer</i> , 2018, 18, 1117.	1.1	16
34	Identity Inclusiveness and Centrality: Investigating Identity Correlates of Attitudes toward Immigrants and Immigration Policies. <i>Journal of Social Issues</i> , 2018, 74, 674-699.	1.9	20
35	Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2018, 11, 99.	6.9	35
36	Identity and Deprovincialization: Identity Complexity and Inclusiveness Encourage EU-Wide Behavioural Intentions via Reduced Intergroup Concerns and Increased Optimism. <i>International Review of Social Psychology</i> , 2018, 31, .	1.1	3

#	ARTICLE	IF	CITATIONS
37	Effects of Past and Present Intergroup Communication on Perceived Fit of an Outgroup Member and Desire for Future Intergroup Contact. <i>Communication Research</i> , 2017, 44, 530-555.	3.9	22
38	Socially creative appraisals of rejection bolster ethnic migrants' subjective well-being. <i>Journal of Applied Social Psychology</i> , 2017, 47, 366-376.	1.3	13
39	An exploratory study of the relations between women miners' gender-based workplace issues and their mental health and job satisfaction. <i>Journal of Applied Social Psychology</i> , 2017, 47, 400-411.	1.3	4
40	Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study. <i>Leukemia Research</i> , 2017, 62, 77-83.	0.4	15
41	Chromothripsis in acute myeloid leukemia: Biological features and impact on survival. <i>Leukemia</i> , 2017, , .	3.3	3
42	The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report. <i>BMC Cancer</i> , 2017, 17, 523.	1.1	2
43	First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2017, 130, 99-99.	0.6	63
44	Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 53377-53391.	0.8	34
45	<scp>FGFR</scp>1 and <scp>KAT6A</scp> rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features. <i>American Journal of Hematology</i> , 2016, 91, E14-6.	2.0	4
46	Changing people's views of outgroups through individual-to-group generalisation: meta-analytic reviews and theoretical considerations. <i>European Review of Social Psychology</i> , 2016, 27, 63-115.	5.8	30
47	Uncovering the diverse cultural bases of social identity: Ingroup ties predict self-stereotyping among individualists but not among collectivists. <i>Asian Journal of Social Psychology</i> , 2016, 19, 225-234.	1.1	3
48	Self-Expansion and Intergroup Contact: Expectancies and Motives to Self-Expand Lead to Greater Interest in Outgroup Contact and More Positive Intergroup Relations. <i>Journal of Social Issues</i> , 2016, 72, 450-471.	1.9	43
49	Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2479-2486.	0.9	3
50	Learning anxiety in interactions with the outgroup: Towards a learning model of anxiety and stress in intergroup contact. <i>Group Processes and Intergroup Relations</i> , 2016, 19, 275-313.	2.4	43
51	Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations. <i>Blood</i> , 2016, 128, 1678-1678.	0.6	0
52	Parents with serious mental illness: Differences in internalised and externalised mental illness stigma and gender stigma between mothers and fathers. <i>Psychiatry Research</i> , 2015, 225, 723-733.	1.7	37
53	Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. <i>American Journal of Hematology</i> , 2015, 90, 515-523.	2.0	51
54	Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients. <i>Oncotarget</i> , 2015, 6, 31284-31294.	0.8	18

#	ARTICLE	IF	CITATIONS
55	Conditioning regimens in acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2014, 7, 465-479.	1.0	1
56	Daunorubicin for the treatment of acute myeloid leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 1075-1087.	0.5	0
57	Positive and extensive intergroup contact in the past buffers against the disproportionate impact of negative contact in the present. <i>European Journal of Social Psychology</i> , 2014, 44, 548-562.	1.5	143
58	Negative intergroup contact is more influential, but positive intergroup contact is more common: Assessing contact prominence and contact prevalence in five Central European countries. <i>European Journal of Social Psychology</i> , 2014, 44, 536-547.	1.5	191
59	Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. <i>Leukemia Research</i> , 2014, 38, 581-585.	0.4	20
60	Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. <i>Cancer</i> , 2014, 120, 1002-1009.	2.0	116
61	Out-Group Flies in the In-Group's Ointment. <i>Social Psychology</i> , 2014, 45, 265-273.	0.3	5
62	The Effects of Teachers' Motivational Strategies on Learners' Motivation: A Controlled Investigation of Second Language Acquisition. <i>Language Learning</i> , 2013, 63, 34-62.	1.4	85
63	Experimental investigation of parents and their children's social interaction intentions towards obese children. <i>Journal of Paediatrics and Child Health</i> , 2013, 49, 604-607.	0.4	2
64	Linguistic Description Moderates the Evaluations of Counterstereotypical People. <i>Social Psychology</i> , 2013, 44, 289-298.	0.3	12
65	Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis. <i>Blood</i> , 2013, 122, 2622-2622.	0.6	11
66	Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy. <i>Blood</i> , 2013, 122, 380-380.	0.6	2
67	Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience. <i>Blood</i> , 2013, 122, 3911-3911.	0.6	0
68	The Contact Caveat. <i>Personality and Social Psychology Bulletin</i> , 2012, 38, 1629-1643.	1.9	486
69	The experiences of Australian parents with psychosis: The second Australian national survey of psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 890-900.	1.3	58
70	First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation. <i>Journal of Blood Medicine</i> , 2012, 3, 151.	0.7	12
71	Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care?. <i>Expert Review of Hematology</i> , 2012, 5, 353-355.	1.0	16
72	FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. <i>Leukemia Research</i> , 2012, 36, 37-41.	0.4	5

#	ARTICLE	IF	CITATIONS
73	Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.. Blood, 2012, 120, 2601-2601.	0.6	4
74	PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience. Blood, 2012, 120, 1749-1749.	0.6	0
75	Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients. Blood, 2012, 120, 1289-1289.	0.6	0
76	Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL).. Blood, 2012, 120, 2497-2497.	0.6	0
77	Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood, 2011, 118, 3273-3279.	0.6	356
78	Pathobiology of acute lymphoblastic leukemia. Seminars in Diagnostic Pathology, 2011, 28, 124-134.	1.0	11
79	SNPs Array Karyotyping Reveals a Novel Recurrent 20p13 Amplification in Primary Myelofibrosis. PLoS ONE, 2011, 6, e27560.	1.1	5
80	Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leukemia and Lymphoma, 2011, 52, 325-327.	0.6	83
81	Secondary transfer effects from imagined contact: Group similarity affects the generalization gradient. British Journal of Social Psychology, 2011, 50, 180-189.	1.8	99
82	CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia Patients. Clinical Cancer Research, 2011, 17, 7413-7423.	3.2	62
83	Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica, 2011, 96, 552-557.	1.7	84
84	The relationship between the need for closure and deviant bias: An investigation of generality and process. International Journal of Psychology, 2011, 46, 206-213.	1.7	10
85	Complete paraplegia after Nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. American Journal of Hematology, 2010, 85, 608-608.	2.0	29
86	Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration. Leukemia Research, 2010, 34, e246-e247.	0.4	5
87	B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. Leukemia Research, 2010, 34, e282-e285.	0.4	37
88	European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy. Journal of Clinical Oncology, 2010, 28, 2389-2395.	0.8	148
89	The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party. Haematologica, 2010, 95, 1683-1690.	1.7	51
90	A processing fluency explanation of bias against migrants. Journal of Experimental Social Psychology, 2010, 46, 21-28.	1.3	82

#	ARTICLE	IF	CITATIONS
91	Negative Intergroup Contact Makes Group Memberships Salient: Explaining Why Intergroup Conflict Endures. <i>Personality and Social Psychology Bulletin</i> , 2010, 36, 1723-1738.	1.9	331
92	Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study. <i>Blood</i> , 2010, 116, 4029-4029.	0.6	1
93	Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen. <i>Blood</i> , 2010, 116, 4335-4335.	0.6	1
94	The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients. <i>Blood</i> , 2010, 116, 3136-3136.	0.6	0
95	RASGRP1/APTX Ratio Is a Strong Biomarker of Clinical Response and Survival In AML Patients Treated with Tipifarnib: A Phase III Preliminary Results. <i>Blood</i> , 2010, 116, 4359-4359.	0.6	0
96	Pediatric Therapy In Adult Acute Lymphoblastic Leukemia: Updated Experience of a Single Centre. <i>Blood</i> , 2010, 116, 4338-4338.	0.6	21
97	Successful combination treatment of clofarabine, cytarabine, and gemtuzumab+azogamicin in adult refractory B-acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2009, 84, 849-850.	2.0	12
98	Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1+ positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). <i>Blood</i> , 2009, 114, 2159-2167.	0.6	201
99	IKZF1 (Ikaros) Deletions in BCR-ABL1+ Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report. <i>Journal of Clinical Oncology</i> , 2009, 27, 5202-5207.	0.8	276
100	Accountability moderates member-to-group generalization: Testing a dual process model of stereotype change. <i>Journal of Experimental Social Psychology</i> , 2009, 45, 676-685.	1.3	20
101	Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. <i>Blood</i> , 2009, 114, 2168-2171.	0.6	160
102	Chronic Eosinophilic Leukaemia (CEL) with FIP1L1-PDGFRalpha Rearrangement (F/P): The Response to Imatinib (IM) Is Durable. A Report of 33 Patients with A Follow up of 30 to 92 Months.. <i>Blood</i> , 2009, 114, 3894-3894.	0.6	1
103	Four Drugs Combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 65 Ys: Response and Follow-up of 84 Patients.. <i>Blood</i> , 2009, 114, 4147-4147.	0.6	0
104	PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party.. <i>Blood</i> , 2009, 114, 12-12.	0.6	2
105	Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients.. <i>Blood</i> , 2009, 114, 2384-2384.	0.6	0
106	RASGRP1/APTX Ratio Strongly Correlates with Clinical Response and Survival in AML Patients Treated with Tipifarnib-Bortezomib Combination.. <i>Blood</i> , 2009, 114, 1028-1028.	0.6	1
107	Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. <i>Blood</i> , 2008, 112, 3847-3855.	0.6	99
108	Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fludarabine: retrospective analysis of 224 cases. <i>European Journal of Haematology</i> , 2008, 81, 354-363.	1.1	29

#	ARTICLE	IF	CITATIONS
109	Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. <i>Hematology</i> , 2008, 13, 1-12.	0.7	2
110	Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: A diagnostic and therapeutic challenge. <i>Leukemia and Lymphoma</i> , 2008, 49, 159-162.	0.6	13
111	Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. <i>Haematologica</i> , 2008, 93, 1814-1821.	1.7	39
112	Identification and Molecular Characterization of Two Recurrent Genomic Deletions (Type A and Type) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Behalf of the GIMEMA ALL Working Party. <i>Blood</i> , 2008, 112, 428-428.	0.6	0
113	Induction Intensified Regimens Including Fludarabine or Mylotarg for Acute Myeloid Leukemia Patients: Comparison by Response and Follow-up.. <i>Blood</i> , 2008, 112, 941-941.	0.6	0
114	Phase I/II Study of Tipifarnib and Bortezomib in the Treatment of Poor Risk Adult Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 2982-2982.	0.6	2
115	Gemtuzumab-Ozogamicin in Combination with Fludarabine, Cytarabine, Idarubicin (FLAI-GO) as Induction Therapy in CD33-Positive AML patients Younger Than 65 Years. Report of a Multicentric Trial. <i>Blood</i> , 2008, 112, 3998-3998.	0.6	0
116	Different Isoforms of the B-Cell Mutator Activation-Induced Cytidine Deaminase (AID) Are Aberrantly Over-Expressed in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients and Promote Genetic Instability.. <i>Blood</i> , 2008, 112, 1497-1497.	0.6	0
117	Extreme Variability of FIP1L1-PDGFRalpha Transcripts Do Not Influence to Imatinib Mesylate Response in CEL: Clinical Follow-up and Molecular Analysis of the Italian Multicenter Prospective Study. <i>Blood</i> , 2008, 112, 5223-5223.	0.6	0
118	Imatinib mesylate in the treatment of hematologic malignancies. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1597-1611.	1.4	23
119	Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. <i>Haematologica</i> , 2007, 92, 401-404.	1.7	172
120	Reducing prejudice via direct and extended cross-group friendship. <i>European Review of Social Psychology</i> , 2007, 18, 212-255.	5.8	168
121	Direct and Indirect Intergroup Friendship Effects: Testing the Moderating Role of the Affective-Cognitive Bases of Prejudice. <i>Personality and Social Psychology Bulletin</i> , 2007, 33, 1406-1420.	1.9	102
122	The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR α -positive hypereosinophilic syndrome. Results of a multicenter prospective study. <i>Haematologica</i> , 2007, 92, 1173-1179.	1.7	198
123	Hypereosinophilic Syndrome and Molecularly Targeted Therapy. <i>Seminars in Hematology</i> , 2007, 44, S4-S16.	1.8	17
124	Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. <i>Lancet Oncology</i> , The, 2007, 8, 273-274.	5.1	39
125	Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study.. <i>Haematologica</i> , 2007, 92, 1721-1722.	1.7	15
126	Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome \hat{e} positive adult acute lymphoblastic leukemia. <i>Cancer</i> , 2007, 110, 1178-1186.	2.0	81

#	ARTICLE	IF	CITATIONS
127	Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B. <i>Journal of Infection</i> , 2006, 53, e243-e246.	1.7	38
128	Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients. <i>Clinical Cancer Research</i> , 2006, 12, 3037-3042.	3.2	90
129	Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome-Positive Leukemia. <i>Journal of Clinical Oncology</i> , 2006, 24, e51-e52.	0.8	61
130	Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts).. <i>Blood</i> , 2006, 108, 836-836.	0.6	17
131	FLT-3 Activity and Its Response to Drugs Can Be Determined in AML Blast Cells by FLT-3 Phosphorylation Status Using Flow Cytometry.. <i>Blood</i> , 2006, 108, 2308-2308.	0.6	0
132	NPM Mutations and Not FLT3 Mutations Are a Potential Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia.. <i>Blood</i> , 2006, 108, 2016-2016.	0.6	0
133	Prevalence and Prognostic Significance of FLT3 Mutations in Acute Myeloid Leukemia: Association of ITDs with Poor Outcome in Patients with Normal Cytogenetics.. <i>Blood</i> , 2006, 108, 2017-2017.	0.6	0
134	Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?. <i>Blood</i> , 2005, 105, 904-905.	0.6	9
135	Grandparent-Grandchild Contact and Attitudes Toward Older Adults: Moderator and Mediator Effects. <i>Personality and Social Psychology Bulletin</i> , 2005, 31, 393-406.	1.9	199
136	Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.. <i>Blood</i> , 2005, 106, 375-375.	0.6	3
137	Effects of Direct and Indirect Cross-Group Friendships on Judgments of Catholics and Protestants in Northern Ireland: The Mediating Role of an Anxiety-Reduction Mechanism. <i>Personality and Social Psychology Bulletin</i> , 2004, 30, 770-786.	1.9	436
138	Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia. <i>European Journal of Haematology</i> , 2004, 72, 302-303.	1.1	2
139	Increased group dispersion after exposure to one deviant group member: Testing Hamburger's model of member-to-group generalization. <i>Journal of Experimental Social Psychology</i> , 2004, 40, 569-585.	1.3	22
140	Efficacy and Toxicity of FLAI-G-CSF and Mylotarg for Induction/Consolidation of AML Patients, Not Treatable with Conventional Chemotherapy.. <i>Blood</i> , 2004, 104, 4514-4514.	0.6	0
141	The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. <i>Haematologica</i> , 2004, 89, 1269-71.	1.7	8
142	Inclusiveness and crossed categorization: Effects on co-joined category evaluations of in-group and out-group primes. <i>British Journal of Social Psychology</i> , 2003, 42, 25-38.	1.8	11